The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
“Although various mechanisms, including neuroinflammation, oxidative stress, autoimmunity, a defect in neuronal glutamate transport and glutamate toxicity, neurofilament accumulation, exogenous factors (viruses, toxins), mitochondrial dysfunction, and mutations in the SOD gene were implicated to play a role, the pathog…”
BackgroundAmyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
“In a small subset of familial Alzheimer's disease (FAD) cases, mutations have been identified in genes that encode the amyloid precursor protein (APP), presenilin-1 (PS1) or PS2 (Ref”
BackgroundHeras-Sandoval, D., Pérez-Rojas, J. M., Hernández-Damián, J., & Pedraza-Chaverri, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.019 · Cited by 1,091
ER stress and the unfolded protein response in neurodegeneration
Hetz, C., & Saxena, S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.99 · Cited by 1,013
Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide
Krewski, D., Yokel, R. A., Nieboer, E., Borchelt, D., Cohen, J., Harry, J., Kacew, S., Lindsay, J., Mahfouz, A. M., & Rondeau, V. (2007) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400701597766 · Cited by 998
“Early onset AD is strongly linked to mutations in 3 genes, with autosomal-dominant inheritance patterns ( Bertram & Tanzi, 2004 ; 2005 ).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Self-citationapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771
“Discussion APOE genotype is the only established genetic risk factor for late-onset sporadic AD with an isoform-specific risk profile of apoE4>apoE3>apoE2 (21, 38, 39).”
BackgroundThe genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676
“In SAD, various susceptibility genes have been identified, including apolipoprotein E ( APOE”
BackgroundHarish, V., Tewari, D., Gaur, M., Yadav, A. B., Swaroop, S., Bechelany, M., & Barhoum, A. (2022) · Nanomaterials · doi:10.3390/nano12030457 · Cited by 623
“Any angiogenesis impairment will result in a chronic wound [252].”
BackgroundAlzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
A Molecular Web: Endoplasmic Reticulum Stress, Inflammation, and Oxidative Stress
Chaudhari, N., Talwar, P., Parimisetty, A., Lefebvre d’Hellencourt, C., & Ravanan, P. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00213 · Cited by 600
“The complications underlying neurodegenerative disorders are multifactorial and may include genetic predisposition (Bertram and Tanzi, 2005; Lill and Bertram, 2011), environmental factors (Cannon and Greenamyre, 2011), cellular stressors such as oxidative stress and free radical production (Gandhi…”
BackgroundSignificance of long chain polyunsaturated fatty acids in human health
Zárate, R., el Jaber‐Vazdekis, N., Tejera, N., Pérez, J. A., & Rodríguez, C. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0153-6 · Cited by 551
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
“Epidemiological studies have revealed that PD is world-wide and affects 1–2% of those older than 65 years, and 4–5% of those aged over 85 years [8, 25].”
BackgroundAdvances in multimodal data fusion in neuroimaging: Overview, challenges, and novel orientation
Zhang, Y.-D., Dong, Z., Wang, S.-H., Yu, X., Yao, X., Zhou, Q., Hu, H., Li, M., Jiménez-Mesa, C., Ramirez, J., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.07.006 · Cited by 453
“Second, a disease, disorder, or lesion may manifest itself in different forms, symptoms, or etiology; or on the other hand, different diseases may share some common symptoms or appearances [2, 3] .”
Current and Novel Polymeric Biomaterials for Neural Tissue Engineering
Boni, R., Ali, A., Shavandi, A., & Clarkson, A. N. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0491-8 · Cited by 439
A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis
Di Fede, G., Catania, M., Morbin, M., Rossi, G., Suardi, S., Mazzoleni, G., Merlin, M., Giovagnoli, A. R., Prioni, S., Erbetta, A., et al. (2009) · Science · doi:10.1126/science.1168979 · Cited by 416
Goldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
Miklossy, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-90 · Cited by 355
“Various hypotheses were proposed to explain the pathogenesis of AD [40,41].”
BackgroundMolecular Basis of Familial and Sporadic Alzheimer's Disease
Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., & Kozubski, W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314150501 · Cited by 329
Advancing translational research with the Semantic Web
Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Chen, H., Doherty, D., Forsberg, K., Gao, Y., Kashyap, V., et al. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s3-s2 · Cited by 328
“Increasingly, researchers recognize that Ad, PD, and HD share various features at the clinical [13], neural [14-17], cellular [18-20], and molecular levels [21,22].”
BackgroundSorting through the Cell Biology of Alzheimer's Disease: Intracellular Pathways to Pathogenesis
Small, S. A., & Gandy, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.001 · Cited by 324
Almeida, C. G., Takahashi, R. H., & Gouras, G. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5078-05.2006 · Cited by 316
Potential of Raman spectroscopic techniques to study proteins
Kuhar, N., Sil, S., & Umapathy, S. (2021) · Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119712 · Cited by 290
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
RNA-Seq and human complex diseases: recent accomplishments and future perspectives
Costa, V., Aprile, M., Esposito, R., & Ciccodicola, A. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.129 · Cited by 269
Dendritic spines: Revisiting the physiological role
Chidambaram, S. B., Rathipriya, A. G., Bolla, S. R., Bhat, A., Ray, B., Mahalakshmi, A. M., Manivasagam, T., Thenmozhi, A. J., Essa, M. M., Guillemin, G. J., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.005 · Cited by 255
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242
Genome-Wide Association Studies in Alzheimer Disease
Waring, S. C., & Rosenberg, R. N. (2008) · Archives of Neurology · doi:10.1001/archneur.65.3.329 · Cited by 236
“As expected with most common complex diseases with onset later in life,(29) late-onset AD likely results from genetic variants with modest effect size that, while statistically significant, are neither sufficient nor necessary to explain all occurrences of disease.(30) It is therefore incumbent that the synthesis and…”
Bossers, K., Wirz, K. T. S., Meerhoff, G. F., Essing, A. H. W., van Dongen, J. W., Houba, P., Kruse, C. G., Verhaagen, J., & Swaab, D. F. (2010) · Brain · doi:10.1093/brain/awq258 · Cited by 230
Lu, Q., Li, B., Ou, D., Erlendsdottir, M., Powles, R. L., Jiang, T., Hu, Y., Chang, D., Jin, C., Dai, W., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.11.001 · Cited by 221
Emerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 201
“Various hypotheses have been proposed to explain the pathogenesis of AD (Refs 37, 38, 39, 40, 41, 42, 43).”
BackgroundBenefits of curcumin in brain disorders
Bhat, A., Mahalakshmi, A. M., Ray, B., Tuladhar, S., Hediyal, T. A., Manthiannem, E., Padamati, J., Chandra, R., Chidambaram, S. B., & Sakharkar, M. K. (2019) · BioFactors · doi:10.1002/biof.1533 · Cited by 197
“Common symptoms include involuntary movements, abnormalities in gait, posture, and balance, obsessive–compulsive behavior, and memory loss.(97) Subcellular actions like oxidative stress, mitochondrial dysfunction, inflammation, and transcriptional dysregulation play a major role in the progression of HD.”
BackgroundLee, C.-T., Bendriem, R. M., Wu, W. W., & Shen, R.-F. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0362-8 · Cited by 192
Bourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
“AD and PD share striking common features despite diverse clinical symptoms and transmission mode (Bertram and Tanzi, 2005).”
BackgroundRole of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders
Mor, A., Tankiewicz-Kwedlo, A., Krupa, A., & Pawlak, D. (2021) · Cells · doi:10.3390/cells10071603 · Cited by 187
In vivo modulation of the Parkinsonian phenotype by Nrf2
Burton, N. C., Kensler, T. W., & Guilarte, T. R. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.07.019 · Cited by 187
The impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185
Mercado, G., Castillo, V., Soto, P., López, N., Axten, J. M., Sardi, S. P., Hoozemans, J. J. M., & Hetz, C. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.004 · Cited by 179
“amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Prionrelated disorders (PrDs), Huntington's disease among others (Bertram and Tanzi, 2005; Soto, 2003).”
BackgroundSpuch, C., & Navarro, C. (2011) · Journal of Drug Delivery · doi:10.1155/2011/469679 · Cited by 177
“The most common neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington’s disease, and prion diseases [3].”
BackgroundThe genetics of Alzheimer's disease
Bagyinszky, E., Youn, Y. C., An, S., & Kim, S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s51571 · Cited by 173
“Late-onset Alzheimer’s disease In late-onset Alzheimer’s disease (LOAD), several genes have been described as potential risk factors, but nongenetic factors may also be involved in the disease’s progression (Figure 3).(9) The APOE gene, located on chromosome 19, is an important genetic risk factor for LOAD, and its im…”
Brain Disorders Due to Lysosomal Dysfunction
Fraldi, A., Klein, A. D., Medina, D. L., & Settembre, C. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014031 · Cited by 170
Salivary biomarkers for the diagnosis and monitoring of neurological diseases
Farah, R., Haraty, H., Salame, Z., Fares, Y., Ojcius, D. M., & Said Sadier, N. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.03.004 · Cited by 170
“suggest the involvement of multiple combined factors [1,2].”
BackgroundChronic Inflammation and Amyloidogenesis in Alzheimer's Disease -- Role of Spirochetes1
Miklossy, J. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13404 · Cited by 168
“A variety of scientific hypotheses were proposed to explain the pathogenesis of AD [5,68,88,89,92,102].”
Paulsen, J. S., Nance, M., Kim, J.-I., Carlozzi, N. E., Panegyres, P. K., Erwin, C., Goh, A., McCusker, E., & Williams, J. K. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.08.003 · Cited by 168
Applications of nanomaterials in tissue engineering
Zheng, X., Zhang, P., Fu, Z., Meng, S., Dai, L., & Yang, H. (2021) · RSC Advances · doi:10.1039/d1ra01849c · Cited by 164
Postural Instability in Parkinson’s Disease: A Review
Palakurthi, B., & Burugupally, S. P. (2019) · Brain Sciences · doi:10.3390/brainsci9090239 · Cited by 163
“These symptoms are independent of age at onset, disease duration, and sex [44,79,89,90].”
Backgroundγ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs
Oehlrich, D., Berthelot, D. J.-C., & Gijsen, H. J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101168r · Cited by 161
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161
“The most prevalent genetic risk factor for late-onset AD is the APOE genotype with an allele-specific risk profile: APOE4 >APOE3 >APOE2 [33,34]).”
BackgroundBoutin, H., Chauveau, F., Thominiaux, C., Gregoire, M.-C., James, M. L., Trebossen, R., Hantraye, P., Dolle, F., Tavitian, B., & Kassiou, M. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.036764 · Cited by 160
“Over the past decades, the incidence of neurodegenerative disease in the elderly population of developed countries has increased considerably (1,2).”
BackgroundPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
“Overexpresssion of Aβ due to trisomy 21 in individuals with Down syndrome associates with early-onset AD (Bertram and Tanzi (2005); Hartley et al.”
A Genomewide Screen for Late-Onset Alzheimer Disease in a Genetically Isolated Dutch Population
Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P., Feng, B.-J., Bertoli-Avella, A. M., van Swieten, J., Axenovich, T. I., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518720 · Cited by 156
“These four genes together explain less than a quarter of the disease prevalence, indicating that additional genetic risk factors remain to be identified.(10,11) In addition to APOE, various candidate genes were reported to be associated with late-onset AD.”
BackgroundRay, B., & Lahiri, D. K. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.012 · Cited by 159
Association between Vitamin D Receptor Gene Polymorphism and Alzheimer's Disease
Gezen-Ak, D., Dursun, E., Ertan, T., Hanagasi, H., Gürvit, H., Emre, M., Eker, E., Öztürk, M., Engin, F., & Yilmazer, S. (2007) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.212.275 · Cited by 144
“(Blacker et al. 1998; Hollenbach et al. 1998; Luedecking-Zimmer et al. 2003; Bertram and Tanzi 2005).”
Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
Bayer, T. A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 140
Genetic Aspects of Alzheimer Disease
Williamson, J., Goldman, J., & Marder, K. S. (2009) · The Neurologist · doi:10.1097/nrl.0b013e318187e76b · Cited by 135
“Recent publications have thoroughly explained the steps of mapping genes in common, complex disorders or specifically in AD.(19,32) In order for an association to be confirmed, the positive association must be replicated by independent studies and in different populations.”
BackgroundThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
“Genetic effects on A -deposition are numerous [137, 138].”
BackgroundGenetics of Alzheimer’s Disease
Vilatela, M. E. A., López, M., & Yescas, P. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.017 · Cited by 162
Epidemiology of Parkinson's disease
Kasten, M., Chade, A., & Tanner, C. M. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83006-5 · Cited by 146
“These candidates do not map to known PD linkage regions, but polymorphisms in both genes have been associated with PD in some case-control studies (as reviewed by Bertram and Tanzi, 2005).”
Interaction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 128
“patients with familial AD linked to Ab formation and a higher frequency of AD in people with trisomy 21, who carry an additional APP allele [82].”
BackgroundLessons from Tau-Deficient Mice
Ke, Y. D., Suchowerska, A. K., van der Hoven, J., De Silva, D. M., Wu, C. W., van Eersel, J., Ittner, A., & Ittner, L. M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/873270 · Cited by 127
“While in familial cases of AD (FAD), mutations were found in the APP- and the presenilin genes 1 and 2 [10], the latter being part of the γ-secretase complex [11], mutations in the MAPT gene were found in familial FTD [12, 13].”
BackgroundInfectious agents and Alzheimer's disease
Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102073 · Cited by 123
Maiti, P., Manna, J., Ilavazhagan, G., Rossignol, J., & Dunbar, G. L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.020 · Cited by 138
Mitophagy and cGAS–STING crosstalk in neuroinflammation
Zhou, X., Wang, J., Yu, L., Qiao, G., Qin, D., Yuen-Kwan Law, B., Ren, F., Wu, J., & Wu, A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.012 · Cited by 131
“These challenges span from the fundamental barriers posed by the brain’s protective mechanisms to the intricacies of individual genetic variability 305,306 .”
BackgroundRole of Epigenetics in Alzheimer ‘S and Parkinson‘S Disease
Kwok, J. B. (2010) · Epigenomics · doi:10.2217/epi.10.43 · Cited by 119
New Insights in the Amyloid-Beta Interaction with Mitochondria
Spuch, C., Ortolano, S., & Navarro, C. (2012) · Journal of Aging Research · doi:10.1155/2012/324968 · Cited by 117
“The most common neurodegenerative diseases are AD, Parkinson disease, Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis [2].”
BackgroundRole of Cholesterol in APP Metabolism and Its Significance in Alzheimer’s Disease Pathogenesis
Maulik, M., Westaway, D. A., Jhamandas, J. H., & Kar, S. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8337-y · Cited by 129
“its prevalence doubles every 5 years thereafter [4, 5].”
BackgroundNeuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 141
“Moreover, current animal models of NDs cannot fully replicate the complex pathogenic lesions of human NDs, and often overlook sporadic cases, which account for most cases 22,23 .”
BackgroundTau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
“Overwhelming data suggests that molecular changes occurring in response to aging may promote taupathy (Bertram and Tanzi, 2005).”
Scaramuzzino, C., Monaghan, J., Milioto, C., Lanson, N. A., Maltare, A., Aggarwal, T., Casci, I., Fackelmayer, F. O., Pennuto, M., & Pandey, U. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061576 · Cited by 116
“Intracellular and extracellular aggregation and deposition of misfolded protein are hallmarks of many human neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, frontotemporal lobar degeneration, polyglutamine diseases, and ALS [40,41].”
BackgroundYeung, A. W. K., Tzvetkov, N. T., Georgieva, M. G., Ognyanov, I. V., Kordos, K., Jóźwik, A., Kühl, T., Perry, G., Petralia, M. C., Mazzon, E., et al. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7952 · Cited by 110
Munoz-Sanjuan, I., & Bates, G. P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45364 · Cited by 109
Transgenic Drosophila models of Alzheimer’s disease and tauopathies
Iijima‐Ando, K., & Iijima, K. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0234-4 · Cited by 128
“Less than 10% of all AD cases are inherited in an autosomal dominant manner (Bertram and Tanzi 2005).”
Cu2+ Affects Amyloid-β (1–42) Aggregation by Increasing Peptide-Peptide Binding Forces
Hane, F., Tran, G., Attwood, S. J., & Leonenko, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059005 · Cited by 107
“Genetic factors [10], metals [5,11], and vascular deficiencies [12] have been found to be associated with AD.”
Epigenetics in neurodegeneration: A new layer of complexity
Marques, S., Oliveira, C. R., Pereira, C., & Outeiro, T. F. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.008 · Cited by 115
“1) (Bertam and Tanzi, 2005).”
The potential role of epigenomic dysregulation in complex human disease
Hatchwell, E., & Greally, J. M. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.08.010 · Cited by 116
“With the reasonable assumption that DNA sequence changes should encode heritable disease susceptibility, the mutations responsible for certain complex disorders have been found; good examples are Alzheimer’s [3,4] and Parkinson’s diseases(reviewedinreference[ 5 ]).Itisassumedthatcomplex disordersresultfrom theinvolvem…”
BackgroundDNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro
Coupland, K., Mellick, G. D., Silburn, P. A., Mather, K. A., Armstrong, N. J., Sachdev, P. S., Brodaty, H., Huang, Y. M., Halliday, G. M., Hallupp, M., et al. (2013) · Movement Disorders · doi:10.1002/mds.25784 · Cited by 108
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by tremor and bradykinesia that affects 2% of the population over the age of 65 years.(1) The neuropathologic hallmarks for PD are a loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies, cytoplasmic inclu…”
BackgroundThe role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention
Huang, Y., Todd, N., & Thathiah, A. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.02.001 · Cited by 113
Football Increases the Risk for Lou Gehrig's Disease, Amyotrophic Lateral Sclerosis
Abel, E. L. (2007) · Perceptual and Motor Skills · doi:10.2466/pms.104.4.1251-1254 · Cited by 98
Islam, B. U., Habib, S., Ahmad, P., Allarakha, S., Moinuddin, M., & Ali, A. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-014-0475-8 · Cited by 111
Iijima, K., Gatt, A., & Iijima-Ando, K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq200 · Cited by 96
“Molecular genetic studies of early-onset familial AD patients have identified causative mutations in APP, Presenilin 1 and Presenilin 2 (6), which increase Ab42 production and/or Ab aggregation (7,8).”
BackgroundAdvances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Spuch, C., Ortolano, S., & Navarro, C. (2012) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221112799219125 · Cited by 108
“Approximately 24 million people worldwide suffer from dementia, 60% of cases being due to AD, which occurs in 1% of individuals aged 50 to 70 and dramatically increases to 50% for those over 70 years [4].”
BackgroundWang, K., Zhu, L., Zhu, X., Zhang, K., Huang, B., Zhang, J., Zhang, Y., Zhu, L., Zhou, B., & Zhou, F. (2013) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-0006-9 · Cited by 99
Halim, A., Qu, K.-Y., Zhang, X.-F., & Huang, N. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00490 · Cited by 99
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases
Yang, S., Park, J. H., & Lu, H.-C. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00634-3 · Cited by 94
“unhealthy lifestyle [26], free radical or neurotoxicants exposures [27]), disease-associated genetic mutations [28], or epigenetic modifications [29] result in NDAs.”
Backgroundde Araújo Boleti, A. P., de Oliveira Flores, T. M., Moreno, S. E., Anjos, L. D., Mortari, M. R., & Migliolo, L. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104714 · Cited by 92
Prevention of common neurodegenerative disorders in the elderly
Fratiglioni, L., & Qiu, C. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.06.006 · Cited by 111
“Parkinson’s disease, which is the second most common degenerative disease, shares common features in aspects such as genetic, and environmental risk factors with other types of degenerative dementia (Bertram and Tanzi, 2005; Brown et al., 2005).”
InfluentialCalabrese, G., Molzahn, C., & Mayor, T. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102062 · Cited by 91
“In the past few decades, many of the genetic and biochemical causes underlying NDs associated with protein aggregation were uncovered, leading to the distinction between rarer familial forms, where disease-causing mutations are genetically inherited, and the more common sporadic forms, where genetic and environmental…”
BackgroundPinto, M., Silva, V., Barreiro, S., Silva, R. V. D. S., Remião, F., Borges, F., & Fernandes, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101658 · Cited by 99
Horrocks, M. H., Tosatto, L., Dear, A. J., Garcia, G. A., Iljina, M., Cremades, N., Serra, M. D., Knowles, T. P. J., Dobson, C. M., & Klenerman, D. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01811 · Cited by 93
Coupland, K., Kim, W. S., Halliday, G. M., Hallupp, M., Dobson‐Stone, C., & Kwok, J. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157924 · Cited by 95
Twenty-Five Years of Progress: The View from NIMH and NINDS
Insel, T. R., & Landis, S. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.041 · Cited by 85
An update on clinical proteomics in Alzheimer’s research
Korolainen, M. A., Nyman, T. A., Aittokallio, T., & Pirttilä, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06558.x · Cited by 86
“All AD causing mutations are linked to amyloid pathology in AD (Nilsberth et al. 2001; Bertram and Tanzi 2005).”
BackgroundKumari, S., Goyal, V., Kumaran, S. S., Dwivedi, S. N., Srivastava, A. K., & Jagannathan, N. R. (2020) · Neurological Sciences · doi:10.1007/s10072-019-04143-4 · Cited by 92
Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Martier, R., & Konstantinova, P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580179 · Cited by 65
“Examples of the most common neurodegenerative diseases are amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), spinocerebellar ataxias (SCAs), Huntington’s disease (HD), Alzheimer’s disease (AD), and Parkinson’s disease (PD) (Bertram and Tanzi, 2005).”
BackgroundRecent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160882 · Cited by 84
Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model
Griñán-Ferré, C., Corpas, R., Puigoriol-Illamola, D., Palomera-Ávalos, V., Sanfeliu, C., & Pallàs, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170664 · Cited by 83
“Neuropathological hallmarks of AD include lesions such as the presence of intracellular neurofibrillary tangles and the accumulation of A plaques in specific brain regions and cerebral amyloid angiopathy, reactive gliosis, and neuroinflammation [16], OS, calcium homeostasis disruption, neuronal and synaptic loss, alte…”
BackgroundTau at the interface between neurodegeneration and neuroinflammation
Didonna, A. (2020) · Genes & Immunity · doi:10.1038/s41435-020-00113-5 · Cited by 82
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.